Free tool
FAERS Monitor: Susvimo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761197 or its brand name (Susvimo, Ranibizumab). Reports on generic versions are filed under their own applications.
Reports
5,319
Serious
5,059
95% of reports
Hospitalization
1,483
Death reported
751
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- visual acuity reduced545
- death380
- off label use295
- retinal haemorrhage270
- cerebrovascular accident265
- vitreous haemorrhage214
- drug ineffective209
- endophthalmitis207
- myocardial infarction181
- visual impairment172
- cataract164
- retinal pigment epithelial tear149
- fall148
- no adverse event131
- blindness126
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 3 |
| 2007 | 53 |
| 2008 | 67 |
| 2009 | 142 |
| 2010 | 241 |
| 2011 | 240 |
| 2012 | 565 |
| 2013 | 996 |
| 2014 | 442 |
| 2015 | 334 |
| 2016 | 234 |
| 2017 | 193 |
| 2018 | 208 |
| 2019 | 208 |
| 2020 | 129 |
| 2021 | 162 |
| 2022 | 253 |
| 2023 | 277 |
| 2024 | 210 |
| 2025 | 219 |
| 2026 | 143 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,840 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| retinal pigment epithelial tearSignal | 149 | 1081.9 | 904.4 | 125,516 |
| vitreous haemorrhageSignal | 214 | 331.8 | 289.4 | 64,829 |
| retinal haemorrhageSignal | 270 | 155.8 | 138.3 | 39,808 |
| endophthalmitisSignal | 207 | 141.3 | 123.3 | 27,712 |
| visual acuity reducedSignal | 545 | 66.0 | 60.9 | 34,283 |
| blindnessSignal | 126 | 12.3 | 10.3 | 1,291 |
| cataractSignal | 164 | 10.9 | 9.4 | 1,468 |
| cerebrovascular accidentSignal | 265 | 6.2 | 5.5 | 1,156 |
| visual impairmentSignal | 172 | 5.5 | 4.7 | 631 |
| myocardial infarctionSignal | 181 | 4.1 | 3.6 | 425 |
| no adverse eventSignal | 131 | 2.9 | 2.4 | 158 |
| fall | 148 | 1.8 | 1.5 | 48 |
| death | 380 | 1.7 | 1.6 | 125 |
| off label use | 295 | 1.3 | 1.2 | 25 |
| drug ineffective | 209 | 0.6 | 0.5 | 49 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.